TP53 and adenocarcinoma: Recent research discovered that 86% of resected nodules with isolated TP53 mutations were benign, while 82% of nodules carrying TP53 mutations along with other gene alterations were cancerous; although the majority of thyroid nodules containing a single TP53 genetic variant have been shown to be benign adenocarcinomas, there has been speculation that TP53-mutant adenocarcinomas could be precursors to malignancies that have not yet differentiated (25).